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Purpose of the study
To assess the association between antiretroviral therapy,
cardiovascular risk factors and constituents of metabolic
syndrome to IR.
Methods
We studied all patients who had a visit in our outpatient
HIV clinic during 2007. The following data were collected:
age at diagnosis of HIV infection, gender, country of ori-
gin, smoking status, HCV co-infection, HIV risk group,
AIDS diagnosis, CD4+ cell count, HIV viral load, fasting
glucose and insulin levels, lipid profile, blood pressure,
waist circumference, BMI and present HAART. We used
the HOMA index to assess insulin resistance, choosing as
cut-off point 3.8. The IDF criteria have been used to define
increased waist circumference, hypertension, hypertry-
gliceridemia, low HDL cholesterol and hyperglycemia.
We assessed the association of these variables with IR
using a multivariate logistic regression predictive model.
Blood glucose value was not taken into account in the
analysis since it is embedded in the HOMA index. Dis-
criminating power of the model was analyzed by means of
a receiver operating curve (ROC). The effect measure was
the adjusted odds-ratio with 95% confidence interval
(CI).
Summary of results
128 patients were analyzed. Median HOMA index was
2.12 (IQR 1.26–3.39). 75% were males and median age
was 43 years (IQR 39–46). Viral load was below 50 copies
in 78% and median CD4+ count was 397 cel/microL.
Only 8.6% were immigrants. The most prevalent HIV risk
group was intravenous drug use (IDU) (57.8%). 25% had
an AIDS diagnosis and HCV co-infection rate was 64.1%.
Metabolic syndrome, as defined by IDF criteria, was
present in 29.6%. Moreover, 74.2% were smokers. 49%
were taking PI, 34.4% NNRTI and 16.4% NRTI. Hyperten-
sion (OR 2.92, 95% CI 1.04–8.22, P = 0.042), hypertrig-
lyceridemia (OR 2,88, 95% CI 1,01–8,19, P = 0.047),
increased waist circumference (OR 8,33, 95% CI 2,53–
27,5, P = 0.0001) and smoking (OR 3.56, 95% CI 1.03–
12.38, P = 0.046) were associated with an increased risk of
IR. HCV co-infection and HAART were not associated with
IR. The model showed a high predictive power (AUC 0.79,
95% CI 0.69–0.88, P = 0.0001).
Conclusion
1. Patients with HIV infection in our cohort had a higher
prevalence of metabolic syndrome than the prevalence in
the Spanish population (19.3% according to WHO); 2.
These patients have an increased cardiovascular risk due
to high smoking rate; 3. The four factors associated with
IR in HIV patients are hypertension, increased waist cir-
cumference, hypertrigliceridemia and smoking.
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